Abstract

Objective

Local thermal ablation, a minimally invasive technique, has been widely used in clinical treatment of lung cancer. This study aimed to discuss the clinical efficacy of systemic chemotherapy combined with radiofrequency ablation (RFA) versus systemic chemotherapy combined with microwave ablation (MWA) in treating lung cancer.

Methods

A retrospective analysis involving 124 lung cancer patients, who received RFA (n = 68) and MWA (n = 56) combined with systemic chemotherapy in Cangzhou People’s Hospital from August 2017 to December 2019, was conducted. Before comparative analysis for therapeutic efficacy, the two groups of patients were matched with propensity score matching method at a ratio of 1:1. Indicators including progression-free survival (PFS), overall survival (OS), short-term efficacy, tumor marker level, local tumor control rate, and postoperative complications were comparatively analyzed.

Results

There was no statistical difference in disease control rate and objective response rate (90.6% and 78.1% vs 93.8% and 84.4%) between RFA group and MWA group. The incidence of complications was 12.5% in RFA group and 18.8% in MWA group with no statistically significant difference. In addition, the local tumor control rate in MWA group (90.6%) was significantly higher than that in RFA group (78.1%). Regarding survival, a statistically significant difference was observed in median PFS of RFA and MWA groups (9.2 months vs 10.4 months, p < 0.05), while OS in two groups slightly varied.

Conclusion

MWA was superior to RFA over local tumor control rate and PFS and showed great potential in lung cancer ablation treatment.

中文翻译：

---

全身化疗联合射频消融与微波消融治疗肺癌的临床疗效对比研究

摘要

客观的

局部热消融是一种微创技术，已广泛应用于肺癌的临床治疗。本研究旨在探讨全身化疗联合射频消融（RFA）与全身化疗联合微波消融（MWA）治疗肺癌的临床疗效。

方法

回顾性分析 2017年8月至2019年12月在沧州市人民医院接受RFA（n  =68）和MWA（n =56）联合全身化疗的124例肺癌患者。在疗效对比分析前，将两组患者按1:1的比例进行倾向评分匹配法进行匹配。比较分析无进展生存期（PFS）、总生存期（OS）、近期疗效、肿瘤标志物水平、局部肿瘤控制率、术后并发症等指标。

结果

RFA组和MWA组的疾病控制率和客观缓解率（90.6%和78.1% vs 93.8%和84.4%）无统计学差异。RFA组并发症发生率为12.5%，MWA组为18.8%，差异无统计学意义。此外，MWA组肿瘤局部控制率（90.6%）明显高于RFA组（78.1%）。在生存方面，RFA 和 MWA 组的中位 PFS 存在统计学显着差异（9.2 个月 vs 10.4 个月，p  < 0.05），而两组的 OS 略有不同。

结论

MWA 在局部肿瘤控制率和 PFS 方面优于 RFA，在肺癌消融治疗中显示出巨大的潜力。